Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 9/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | VCP | P55072 | 3/20 | 0.47 |
| ▸ | FLT1 | P17948 | 2/20 | 0.46 |
| ▸ | FLT4 | P35916 | 2/20 | 0.46 |
| ▸ | KDR | P35968 | 2/20 | 0.46 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.44 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22925839 | 0.90 | KMT2A (0.52) | TRPV1ALOX5VCPFLT1FLT4 | |
| SCHEMBL22925735 | 0.89 | VCP (0.46) | TRPV1ALOX5VCPFLT1FLT4 | |
| SCHEMBL31013371 | 0.89 | VCP (0.46) | TRPV1ALOX5VCPFLT1FLT4 | |
| SCHEMBL22926099 | 0.88 | ALOX5 (0.60) | ALOX5VCPFLT1FLT4KDR | |
| SCHEMBL29621011 | 0.88 | ALOX5 (0.60) | ALOX5VCPFLT1FLT4KDR | |
| SCHEMBL22925600 | 0.88 | TRPV1 (0.45) | TRPV1ALOX5VCPFLT1FLT4 | |
| SCHEMBL22925617 | 0.88 | VCP (0.46) | TRPV1ALOX5VCPFLT1FLT4 | |
| SCHEMBL22925719 | 0.86 | KMT2A (0.42) | VCPP4HTM | |
| SCHEMBL22925770 | 0.86 | TRPV1 (0.46) | TRPV1ALOX5VCPFLT1FLT4 | |
| SCHEMBL22925694 | 0.86 | VCP (0.46) | TRPV1ALOX5VCPKDRDGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114450281-B | Inhibitor compounds | 辛塞拉治疗私人有限公司 | 2024-08-16 | — | — | CN | disclosed |
| US-20220274970-A1 | INHIBITOR COMPOUNDS | Cincera Therapeutics Pty Ltd (AU) | 2022-09-01 | — | — | US | disclosed |
| EP-4003986-A1 | INHIBITOR COMPOUNDS | Cincera Therapeutics Pty Ltd (AU) | 2022-06-01 | — | — | EP | disclosed |
| CN-114450281-A | Inhibitor compounds | 辛塞拉治疗私人有限公司 | 2022-05-06 | — | — | CN | disclosed |
| WO-2021012018-A1 | INHIBITOR COMPOUNDS | Cincera Therapeutics Pty Ltd (AU) | 2021-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220274970-A1 | INHIBITOR COMPOUNDS | SERPINB1, MMP1, SSB | TRPV1 4690/4885ALOX5 1469/4885VCP 595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.